Ironwood Pharma (IRWD) Stock Statistics & Valuation Metrics

Ironwood Pharma has a market cap or net worth of $549.51M. The enterprise value is $931.85M.

Ironwood Pharma has 163,058,320 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ironwood Pharma’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is 11.39%.

The current PE Ratio of Ironwood Pharma is ―. Ironwood Pharma’s PEG ratio is 0.00866.

In the last 12 months, Ironwood Pharma had revenue of 296.15M and earned 24.02M in profits. Earnings per share was 0.15.

In the last 12 months, operating cash flow was 127.04M and capital expenditures -34.00K, giving a free cash flow of 127.01M billion.

Ironwood Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Ironwood Pharma upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).

Ironwood Pharma as a current ratio of 1.13, with Debt / Equity ratio of -228.31%

In the past 12 months, Ironwood Pharma has paid 46.01M in taxes.

Ironwood Pharma EV to EBITDA ratio is 8.88, with an EV/FCF ratio of 7.31.

Ironwood Pharma has $215.46M in cash and marketable securities with $597.80M in debt, giving a net cash position of -$382.35M billion.

Gross margin is 90.58%, with operating margin of 40.10%, and net profit margin of 8.11%.

The average price target for Ironwood Pharma is $7.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy